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The use of metformin as a first line drug in high dosage schedule in underweight individuals is not usually advised not the least for its probable lack of efficacy under such conditions and its reputed anorexic effect. In view of the patient's degree of renal insufficiency not only was metformin contraindicated in March 1984 but so also was her sulphonylurea therapy. Chlorpropamide is a long acting drug cleared largely through the kidneys. The patient should have been changed to a shorter acting sulphonylurea which does not rely on normal renal function to maintain a normal half life.
The patient's biochemistry on presentation was that of acute renal failure with circulatory collapse and hypoglycaemia. There is no evidence presented to suggest that metformin was the direct cause nor that lactic acidosis secondary to metformin therapy was the primary pathology.
The renal failure itself would be sufficient to increase lactic acidaemia, and her presenting arterial pH was sufficiently low to account for further uncontrolled lactic acid production by the liver. At a pH of less than 7.1 the liver becomes a net lactic acid producer as opposed to the main lactate metabolizing group.
J This letter has been shown to Drs Tymms and Leatherdale who reply:
Sir, We thank Drs Broom, Ross and Whiting for their considered comments about our case report but we believe that their conclusions are based on theoretical considerations rather than published evidence. Although it is possible that our patient did have some impairment of renal function, in practice 'clinical risk' is assessed on serum creatinine without measurement of glomerular filtration rate. We are, however, unaware of any report of metformin-related lactic acidosis in a patient whose serum creatinine and urea concentrations were within the normal range, except in cases of metformin overdose' or alcohol abuse.2 In a review of 330 cases of biguanide-related lactic acidosis3 the lowest serum creatinine concentration in the 12 metformin cases was 265 mmol/l and other reports have suggested that metformin-related lactic acidosis occurs only with marked renal impairment. 4 Similarly, we are not aware of any work to show that body weight influences the metabolism or the clearance of metformin from plasma. Pharmacokinetic studies56 have shown that it is renal function which is the main determinant of metformin clearance.
The hypoglycaemia noted on the day of admission was easily corrected and had probably developed because the patient had not eaten breakfast. If the chlorpropamide had accumulated more prolonged hypoglycaemia would have been expected and this was not seen. We believe that metformin was causally related to the lactic acidosis for a number of reasons. The plasma metformin level was very high at 56.8 fig/ml which is twice the value of 261g/ml reported in one other fatal case of metformin-related lactic acidosis.4 Also the lactate level was high and similar to the mean level of 16.9 mmol/l reported in 330 cases of biguanideinduced lactic acidosis.2 These cases had degrees of acidosis and renal failure similar to our case and yet the lactic acidaemia was clearly due to the biguanide drugs. We think it is unlikely that hepatic lactic acid production was significant in our patient as the pH was 7.027 and there is evidence to suggest that significant amounts of lactate are only produced at levels below 7.0. 7 We, of course, agree with the statement that metformin was not an ideal drug for this patient. As reported, she was repeatedly advised to change from oral hypoglycaemic agents to insulin but refused to do this. D.J. Tymms B.A. Leatherdale Royal South Hants Hospital Southampton S09 JBG, UK.
